Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 10, 2014, Pages 1516-1521

  Koreth, John ^a   Kim, Haesook T ^a   Nikiforow, Sarah ^a   Milford, Edgar L ^b   Armand, Philippe ^a   Cutler, Corey ^a   Glotzbecker, Brett ^a   Ho, Vincent T ^a   Antin, Joseph H ^a   Soiffer, Robert J ^a   Ritz, Jerome ^a   Alyea, Edwin P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Allogeneic transplantation; Chimerism; Reduced intensity

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; FLUDARABINE; METHOTREXATE; RAPAMYCIN; TACROLIMUS; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DONOR; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL DYSCRASIA; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; REDUCED INTENSITY CONDITIONING; RELAPSE; RISK FACTOR; SURVIVAL; T LYMPHOCYTE; ALLOTRANSPLANTATION; GENETICS; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ADULT; AGED; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84912573817     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.05.025     Document Type: Article

References (23)

1. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
2. Galimberti S., Benedetti E., Morabito F., et al. Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. Transpl Immunol 2005, 15:173-177.
3. Blau I.W., Schmidt-Hieber M., Leschinger N., et al. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Ann Hematol 2007, 86:583-589.
4. Lange T., Hubmann M., Burkhardt R., et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011, 25:498-505.
5. Holtan S.G., Hogan W.J., Elliott M.A., et al. CD34+ cell dose and establishment of full donor chimerism at day+100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Transplant 2010, 45:1699-1703.
6. Huisman C., de Weger R.A., de Vries L., et al. Chimerism analysis within 6months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 2007, 39:285-291.
7. Saito A.M., Kami M., Mori S., et al. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Am J Hematol 2007, 82:873-880.
8. Mohty M., Avinens O., Faucher C., et al. Predictive factors and impact of full donor T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 2007, 92:1004-1006.
9. Saito B., Fukuda T., Yokoyama H., et al. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan containing reduced-intensity conditioning regimen. Biol Blood Marrow Transplant 2008, 14:1148-1155.
10. Shaffer B.C., Modric M., Stetler-Stevenson M., et al. Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. Exp Hematol 2013, 41:772-778.
11. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. JClin Oncol 2005, 23:1993-2003.
12. Armand P., Gibson C.J., Cutler C., et al. Adisease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012, 120:905-913.
13. Savani B.N., Mielke S., Rezvani K., et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:1216-1223.
14. Le Blanc K., Barrett A.J., Schaffer M., et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant 2009, 15:1108-1115.
15. Kim H.T., Frederick D., Armand P., et al. White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol 2014, 89:591-597.
16. Gray R. Aclass of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
17. Fine J.P., Gray R.J. Aproportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc 1999, 94:496-509.
18. Harrell F.E. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis 2001, Springer, New York.
19. Harrell F.E., Califf R.M., Pryor D.B., et al. Evaluating the yield of medical tests. JAMA 1982, 247:2543-2546.
20. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387.
21. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
22. Armand P., Kim H.T., Logan B.R., et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation: a study from the CIBMTR. Blood 2014, [Epub ahead of print].
23. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data 2002, John Wiley & Sons, New York; Chichester.